![Gary Bridger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gary Bridger
Director/Board Member at
X4 PHARMACEUTICALS, INC.
Net worth: 13 887 $ as of 31/05/2026
Profile
Gary J.
Bridger was the founder of AnorMED, Inc. (1996) as Chief Scientific Officer, VP-R&D.
Current jobs include Director at Expansion Therapeutics, Inc. (2022) and Independent Director at X4 Pharmaceuticals, Inc. (2018).
Former jobs include Director at Arsanis, Inc., Director at X4 Pharmaceuticals, Inc., Director at Celator Pharmaceuticals Corp., Independent Director at Lundbeck Seattle BioPharmaceuticals, Inc. (2013-2016), Independent Director at Aquinox Pharmaceuticals, Inc. (2013-2019), Director at NeurAxon, Inc., Director & Chief Scientific Officer at Liminal BioSciences, Inc. (2022-2023), Director at Presidio Advisors, Inc., Managing Director at Five Corners Capital, Inc., Senior Vice President-Research & Development at Genzyme Corp.
(2006-2007), Executive Vice President-Research & Development at Xenon Pharmaceuticals, Inc. (2013-2015), and Venture Partner at Ventures West Management, Inc. (2010-2012).
Education includes a doctorate from the University of Manchester Institute of Science & Technology (1987).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/03/2026 | 3,222 ( 0% ) | 13 887 $ | 31/05/2026 |
Gary Bridger active positions
| Companies | Position | Start |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Director/Board Member | 01/10/2018 |
Expansion Therapeutics, Inc.
 Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as drug discovery and development company for RNA-mediated diseases | Director/Board Member | 19/01/2022 |
Former positions of Gary Bridger
| Companies | Position | End |
|---|---|---|
| LIMINAL BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 01/09/2023 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Director/Board Member | 09/08/2019 |
| ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 01/01/2016 |
| XENON PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 01/02/2015 |
Ventures West Management, Inc.
 Ventures West Management, Inc. Investment ManagersFinance Ventures West Management invests in early-stage technology companies across Canada. They focus on investments in biotechnology, clean technology and communications. Ventures West Management is an active value-added venture capital partner. The firm contributes resources to ensure that portfolio companies build value. Ventures West often has representation on the board of directors of their portfolio companies. The firm looks for companies with experienced management teams, competitive advantages and attractive markets. They target early-stage companies that are seeking seed or Series A funding. The firm also looks for companies with the potential for a profitable exit within 4 to 6 years | Private Equity Investor | 01/06/2012 |
Training of Gary Bridger
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
48
1st degree connections
16
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 16 |
|---|---|
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops metal based therapeutics | Health Technology |
Liminal BioSciences, Inc.
 Liminal BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops distinctive novel small molecule therapeutics for metabolic, fibrotic and inflammatory diseases | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops and distributes oral small molecule CXCR4 antagonists | Health Technology |
Xenon Pharmaceuticals, Inc.
 Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Ventures West Management, Inc.
Ventures West Management, Inc. Investment ManagersFinance Ventures West Management invests in early-stage technology companies across Canada. They focus on investments in biotechnology, clean technology and communications. Ventures West Management is an active value-added venture capital partner. The firm contributes resources to ensure that portfolio companies build value. Ventures West often has representation on the board of directors of their portfolio companies. The firm looks for companies with experienced management teams, competitive advantages and attractive markets. They target early-stage companies that are seeking seed or Series A funding. The firm also looks for companies with the potential for a profitable exit within 4 to 6 years | Finance |
Celator Pharmaceuticals Corp.
 Celator Pharmaceuticals Corp. BiotechnologyHealth Technology Develops antibody-based therapies to treat cancer | Health Technology |
University of Manchester Institute of Science & Technology
 University of Manchester Institute of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Health Technology |
NeurAxon, Inc.
 NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services Researches and develops nervous system disorder therapies | Commercial Services |
Presidio Advisors, Inc.
 Presidio Advisors, Inc. Investment ManagersFinance Provides investment advice | Finance |
Five Corners Capital, Inc.
 Five Corners Capital, Inc. Investment ManagersFinance Five Corners Capital invests in companies located in North America. The firm targets companies in sectors such as biotechnology, communications, energy technology, and information technology. The firm participates in early-stage capital transactions. | Finance |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as drug discovery and development company for RNA-mediated diseases | Health Technology |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
- Stock Market
- Insiders
- Gary Bridger
Choose MarketScreener 
